2024-11-26 08:00
Biovica, active in cancer monitoring, announces that seven abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest breast cancer meeting, San Antonio Breast Cancer Symposium (SABCS) on December 10-13, 2024...
2024-10-22 08:00
Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) for TKa testing with a UK-based pharma biotech company.
2024-10-03 08:00
Biovica International AB ("Biovica" or the "Company") announces today the outcome of the exercise of warrants of series TO 3 B issued in connection with the Company's rights issue of units during October 2023. In total, 7,441,387 warrants were exercised...
2024-09-24 13:30
Monday, September 30, 2024, is the last day for subscription in Biovica's ongoing warrant program, TO3B. Note that some banks and asset managers may have an earlier deadline date for subscription than 30 September 2024. Shareholders should check this...
2024-09-23 08:00
Biovica, active in blood-based cancer monitoring, has signed a work order with a value of 2.2 MSEK. This is the company’s largest single work order to date for TKa testing services within its Pharma Services business. The work order is signed with a...
2024-09-17 11:00
The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 17 September 2024 and the following resolutions were passed by the meeting.
2024-09-17 08:30
Biovica, active in blood-based cancer monitoring, has signed a Master Service Agreement (MSA) with a US-based biotech company focusing on next generation CDK inhibitors.
2024-09-12 10:25
Significantly increased sales in the USA and much improved cash flow
2024-09-12 08:00
Significantly increased sales in the USA and much improved cash flow
2024-08-16 08:00
The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the annual general meeting to be held on Tuesday 17 September 2024, at 10.00 CET in Conference Hubben's premises on Dag Hammarskjölds Väg 38 in...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects